background image

Paid Clinical Trials South Carolina

Discover 1,324 paid clinical trials in South Carolina. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.

Filter
1

A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

Recruiting
PHASE1
PHASE2

Sponsor:

Nuvalent Inc.

Location:

Durham, Atlanta, Nashville, Washingtonshow 19 more

Code:

NCT05384626

Conditions

Locally Advanced Solid Tumor

Metastatic Solid Tumor

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Interventions

NVL-655

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Recruiting
PHASE1
PHASE2

Sponsor:

Aulos Bioscience, Inc.

Location:

Huntersville, Nashville, Grand Rapids, Houstonshow 2 more

Code:

NCT05267626

Conditions

Advanced Solid Tumor

Metastatic Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

AU-007

Aldesleukin

Avelumab

Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

Recruiting
PHASE3

Sponsor:

GB002, Inc.

Location:

Charleston, Chapel Hill, Durham, Atlantashow 47 more

Code:

NCT05934526

Conditions

Pulmonary Arterial Hypertension

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Placebo

Seralutinib

Generic Dry Powder Inhaler

Primary Subtalar Arthrodesis for Calcaneal Fractures

Recruiting

Sponsor:

Wake Forest University Health Sciences

Location:

Charlotte, Greenville, Concord, Winston-Salemshow 9 more

Code:

NCT06249126

Conditions

Calcaneus Fracture

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Primary Fusion (Open Reduction Internal Fixation (ORIF) + Primary Subtalar Arthrodesis (PSTA)

Open Reduction Internal Fixation (ORIF) only

An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS

Recruiting

Sponsor:

XenoPort, Inc.

Location:

Columbia, Atlanta, Winter Park, Nashvilleshow 8 more

Code:

NCT02560766

Conditions

RLS

Eligibility Criteria

Sex: All

Age: 13 - 17

Healthy Volunteers: Not accepted

Interventions

HORIZANT 300 mg

HORIZANT 600 mg

Placebo

Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

Recruiting
PHASE2
PHASE3

Sponsor:

Biohaven Therapeutics Ltd.

Location:

Charleston, Chapel Hill, Chattanooga, Birminghamshow 27 more

Code:

NCT06309966

Conditions

Focal Epilepsy

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

BHV-7000

Placebo

Epilepsy Journey-An Executive Functioning Intervention for Teens With Epilepsy

Recruiting

Sponsor:

Children's Hospital Medical Center, Cincinnati

Location:

Charleston, Cincinnati, Orange

Code:

NCT06608966

Conditions

Epilepsy in Children

Executive Dysfunction

Eligibility Criteria

Sex: All

Age: 13 - 17

Healthy Volunteers: Not accepted

Interventions

Epilepsy Journey web-based modules

Telehealth with a therapist

A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

Recruiting

Sponsor:

Target PharmaSolutions, Inc.

Location:

Charleston, Asheville, Winston-Salem, Chapel Hillshow 51 more

Code:

NCT03661866

Conditions

Atopic Dermatitis

Alopecia Areata

Hidradenitis Suppurativa

Vitiligo

Psoriasis

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Not accepted

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

Recruiting
PHASE3

Sponsor:

AstraZeneca

Location:

Columbia, Union, Gaffney, Spartanburgshow 195 more

Code:

NCT06283966

Conditions

COPD (Chronic Obstructive Pulmonary Disease)

Eligibility Criteria

Sex: All

Age: 40 - 70+

Healthy Volunteers: Not accepted

Interventions

BGF MDI 320/14.4/9.6 μg

GFF MDI 14.4/9.6 μg

A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors

Recruiting
PHASE1

Sponsor:

Chugai Pharmaceutical

Location:

Augusta, Charleston, Nashville, Houstonshow 1 more

Code:

NCT05735366

Conditions

Solid Tumor

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

SAIL66